StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 11 Jun 2026 07:00:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Takeda's zasocitinib beats deucravacitinib in psoriasis study http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html <p>Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 study for moderate-to-severe plaque psoriasis.</p> <p>The LATITUDE Atlas study enrolled 606 participants who received either zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for 16 weeks. Zasocitinib achieved the primary endpoint of PASI 100 response rate at week 16, with more than 35% of patients achieving complete skin clearance compared to deucravacitinib's response rate, which was 2.5 times lower.</p> <p>The study also showed zasocitinib's statistical superiority for all key secondary endpoints, including PASI 90 response and Static http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html Thu, 11 Jun 2026 07:00:49 -0400 4502 O.00442316 O.00987337 O.05065998 TAK Takeda's zasocitinib beats deucravacitinib in psoriasis study http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html <p>Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 study for moderate-to-severe plaque psoriasis.</p> <p>The LATITUDE Atlas study enrolled 606 participants who received either zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for 16 weeks. Zasocitinib achieved the primary endpoint of PASI 100 response rate at week 16, with more than 35% of patients achieving complete skin clearance compared to deucravacitinib's response rate, which was 2.5 times lower.</p> <p>The study also showed zasocitinib's statistical superiority for all key secondary endpoints, including PASI 90 response and Static http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html Thu, 11 Jun 2026 07:00:49 -0400 4502 O.00442316 O.00987337 O.05065998 TAK Takeda's zasocitinib beats deucravacitinib in psoriasis study http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html <p>Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 study for moderate-to-severe plaque psoriasis.</p> <p>The LATITUDE Atlas study enrolled 606 participants who received either zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for 16 weeks. Zasocitinib achieved the primary endpoint of PASI 100 response rate at week 16, with more than 35% of patients achieving complete skin clearance compared to deucravacitinib's response rate, which was 2.5 times lower.</p> <p>The study also showed zasocitinib's statistical superiority for all key secondary endpoints, including PASI 90 response and Static http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html Thu, 11 Jun 2026 07:00:49 -0400 4502 O.00442316 O.00987337 O.05065998 TAK Takeda's zasocitinib beats deucravacitinib in psoriasis study http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html <p>Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 study for moderate-to-severe plaque psoriasis.</p> <p>The LATITUDE Atlas study enrolled 606 participants who received either zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for 16 weeks. Zasocitinib achieved the primary endpoint of PASI 100 response rate at week 16, with more than 35% of patients achieving complete skin clearance compared to deucravacitinib's response rate, which was 2.5 times lower.</p> <p>The study also showed zasocitinib's statistical superiority for all key secondary endpoints, including PASI 90 response and Static http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html Thu, 11 Jun 2026 07:00:49 -0400 4502 O.00442316 O.00987337 O.05065998 TAK Takeda's zasocitinib beats deucravacitinib in psoriasis study http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html <p>Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) announced that its experimental drug zasocitinib demonstrated statistical superiority over deucravacitinib in a Phase 3 study for moderate-to-severe plaque psoriasis.</p> <p>The LATITUDE Atlas study enrolled 606 participants who received either zasocitinib 30 mg once daily or deucravacitinib 6 mg once daily for 16 weeks. Zasocitinib achieved the primary endpoint of PASI 100 response rate at week 16, with more than 35% of patients achieving complete skin clearance compared to deucravacitinib's response rate, which was 2.5 times lower.</p> <p>The study also showed zasocitinib's statistical superiority for all key secondary endpoints, including PASI 90 response and Static http://www.streetinsider.com/FDA/Takeda%27s+zasocitinib+beats+deucravacitinib+in+psoriasis+study/26632441.html Thu, 11 Jun 2026 07:00:49 -0400 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html <ul class="bwlistdisc"> <li> Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study </li> <li> More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib </li> <li> Safety profile was consistent with previous studies with no new safety signals identified </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54551317&newsitemid=20260611341613&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=644c65b8b85a18ea901aaa9d9f1c9e94" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Significantly+Outperforms+Deucravacitinib+in+Head-to-Head+Phase+3+Psoriasis+Study%2C+Promising+to+Redefine+Oral+Treatment+Expectations/26632401.html Thu, 11 Jun 2026 07:00:00 -0400 4502 4502 O.00442316 O.00987337 O.05065998 TAK FDA accepts Takeda's application for pediatric ENTYVIO treatment http://www.streetinsider.com/Corporate+News/FDA+accepts+Takeda%27s+application+for+pediatric+ENTYVIO+treatment/26624141.html <p>The U.S. Food and Drug Administration has accepted Takeda Pharmaceutical Company's (NYSE:TAK) supplemental Biologics License Application for intravenous ENTYVIO (vedolizumab) to treat moderately to severely active ulcerative colitis and Crohn's disease in pediatric patients ages 2 years and older.</p><p>The FDA has set a Prescription Drug User Fee Act goal date in the first quarter of calendar year 2027 for its review. If approved, ENTYVIO would become the first gut-focused treatment option for this pediatric population.</p><p>Takeda has also submitted a marketing authorization application to the European Medicines Agency for the same pediatric indication and plans to submit applications in additional markets http://www.streetinsider.com/Corporate+News/FDA+accepts+Takeda%27s+application+for+pediatric+ENTYVIO+treatment/26624141.html Tue, 09 Jun 2026 16:30:39 -0400 TAK FDA accepts Takeda's application for pediatric ENTYVIO treatment http://www.streetinsider.com/FDA/FDA+accepts+Takeda%27s+application+for+pediatric+ENTYVIO+treatment/26624141.html <p>The U.S. Food and Drug Administration has accepted Takeda Pharmaceutical Company's (NYSE:TAK) supplemental Biologics License Application for intravenous ENTYVIO (vedolizumab) to treat moderately to severely active ulcerative colitis and Crohn's disease in pediatric patients ages 2 years and older.</p><p>The FDA has set a Prescription Drug User Fee Act goal date in the first quarter of calendar year 2027 for its review. If approved, ENTYVIO would become the first gut-focused treatment option for this pediatric population.</p><p>Takeda has also submitted a marketing authorization application to the European Medicines Agency for the same pediatric indication and plans to submit applications in additional markets http://www.streetinsider.com/FDA/FDA+accepts+Takeda%27s+application+for+pediatric+ENTYVIO+treatment/26624141.html Tue, 09 Jun 2026 16:30:39 -0400 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html <ul class="bwlistdisc"> <li> <b><i>If approved, ENTYVIO would be the only gut-focused treatment for patients two years and older with moderately to severely active ulcerative colitis (UC) or Crohn's disease</i></b> </li> <li> <b><i>Potential for ENTYVIO to address pediatric treatment gaps, reflecting Takeda’s commitment to advancing options where unmet treatment needs remain</i></b> </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (<a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54549720&newsitemid=20260608352333&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0bc8708cf16cbc2b51c2c163757fbf83" shape="rect">TSE:4502/NYSE:TAK</a>) today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for intravenous (IV) ENTYVIO® (vedolizumab) for the treatment of moderately to severely active ulcerative colitis (UC) and Crohn’s disease in pediatric patients http://www.streetinsider.com/Press+Releases/U.S.+FDA+Accepts+Takeda%27s+Application+for+Intravenous+ENTYVIO%C2%AE+%28vedolizumab%29+in+Pediatric+Ulcerative+Colitis+and+Crohn%27s+Disease/26624126.html Tue, 09 Jun 2026 16:30:00 -0400 4502 4502 A.06822034 A.33519386 O.00987337 O.05065998 O.05887791 O.20026344 TAK